TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib

By Dandan Wu, Xuexian O. Yang. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2020

711 citations recorded by the source corpus.

COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.

Subfields: Infectious Diseases, Oncology

View Paper: https://www.semanticscholar.org/paper/33aa7a96bbe963ed38275a54e23d87a9b9bda68f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

In Oncology

Citations in the corpus

Targeting potential drivers of COVID-19: Neutrophil extracellular traps (2020, background): “Neutrophils can shed sIL6Rα in response to IL8 (Marin et al., 2002), which is abundant in the COVID19–associated cytokine storm (Wu and Yang, 2020; Zhang et al., 2020).”
COVID-19: immunopathogenesis and Immunotherapeutics (2020, methodology): “Moreover, baricitinib combined with direct-acting antivirals (lopinavir or ritonavir and remdesivir) were employed for patients with COVID-19 and showed reduced viral replication and aberrant host inflammatory response.(50,77) In T ab le 1.”
COVID-19 and the human innate immune system (2021, background): “…(Xiong et al., 2020) but also in the circulation (IL-1, IFNg, IL-17, TNF, IP-10, MCP-1, G-CSF, GM-CSF, IL-1RA, CCL2, CCL3, CCL5, CCL8, CXCL2, CXCL8, CXCL9, and CXCL16) (Blanco-Melo et al., 2020; Hadjadj et al., 2020; Huang et al., 2020; Wang et al., 2020a; Wu and Yang, 2020; Yang et al., 2020b).”
SARS-CoV-2 infection: The role of cytokines in COVID-19 disease (2020, neutral): “Fedratinib IL-17 Decreasing of IL-17 Wu and Yang [163]”